[SCHEDULE 13G/A] VolitionRX Limited SEC Filing
Lagoda Investment Management, L.P. reports that its managed accounts held 11,705,000 shares of VolitionRX Ltd common stock as of June 30, 2025, representing 11.3% of the outstanding shares. The filing states the Reporting Person has sole voting and sole dispositive power over all 11,705,000 shares. The report cites 103,982,020 shares outstanding for VolitionRX used to calculate the percentage. The Schedule 13G/A indicates the stake is held in the ordinary course of business and was not acquired to influence control of the issuer.
Lagoda Investment Management, L.P. comunica che i suoi conti gestiti detenevano 11.705.000 azioni ordinarie di VolitionRX Ltd al 30 giugno 2025, corrispondenti al 11,3% del capitale sociale in circolazione. La documentazione precisa che la Reporting Person dispone del potere di voto esclusivo e del potere dispositivio esclusivo su tutte le 11.705.000 azioni. Per il calcolo della percentuale il rapporto prende come riferimento un totale di 103.982.020 azioni in circolazione di VolitionRX. Lo Schedule 13G/A indica inoltre che la partecipazione 猫 detenuta nell'ordinario corso dell'attivit脿 e non 猫 stata acquisita con l'intento di influenzare il controllo dell'emittente.
Lagoda Investment Management, L.P. informa que sus cuentas gestionadas pose铆an 11.705.000 acciones ordinarias de VolitionRX Ltd al 30 de junio de 2025, lo que representa el 11,3% del total en circulaci贸n. La presentaci贸n indica que la Persona Informante tiene el voto exclusivo y el poder dispositvo exclusivo sobre las 11.705.000 acciones. Para calcular el porcentaje se usaron 103.982.020 acciones en circulaci贸n de VolitionRX. El Schedule 13G/A se帽ala que la participaci贸n se mantiene en el curso ordinario del negocio y no se adquiri贸 para influir en el control del emisor.
Lagoda Investment Management, L.P.電� 2025雲� 6鞗� 30鞚� 旮办 甏�毽� 瓿勳霌れ澊 VolitionRX Ltd鞚� 氤错喌欤� 11,705,000欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 氚滍枆欤检嫕鞚� 11.3%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊電� 氤搓碃鞚�(Reporting Person)鞚� 鞚� 11,705,000欤� 鞝勲秬鞐� 雽�頃� 雼弲 鞚橁舶甓�瓿� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堧嫟瓿� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 牍勳湪 靷办爼鞐愲姅 VolitionRX鞚� 齑� 氚滍枆欤检嫕靾� 103,982,020欤缄皜 靷毄霅橃棃鞀惦媹雼�. Schedule 13G/A鞐愲姅 鞚� 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾頇滊彊鞚� 鞚柬櫂鞙茧 氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 氚濏瀳瓿� 鞛堨姷雼堧嫟.
Lagoda Investment Management, L.P. rapporte que ses comptes g茅r茅s d茅tenaient 11 705 000 actions ordinaires de VolitionRX Ltd au 30 juin 2025, soit 11,3% des actions en circulation. le dossier pr茅cise que la personne d茅clarante d茅tient le pouvoir de vote exclusif et le pouvoir de disposition exclusif sur l鈥檈nsemble des 11 705 000 actions. Le pourcentage a 茅t茅 calcul茅 sur la base de 103 982 020 actions en circulation de VolitionRX. Le Schedule 13G/A indique par ailleurs que cette participation est d茅tenue dans le cadre normal des activit茅s et n鈥檃 pas 茅t茅 acquise dans le but d鈥檌nfluencer le contr么le de l鈥櫭﹎etteur.
Lagoda Investment Management, L.P. meldet, dass seine verwalteten Konten zum 30. Juni 2025 11.705.000 Stammaktien von VolitionRX Ltd hielten, was 11,3% der ausstehenden Aktien entspricht. Die Einreichung gibt an, dass die meldepflichtige Person 眉ber alle 11.705.000 Aktien alleiniges Stimmrecht und alleinige Verf眉gungsmacht besitzt. Zur Berechnung des Prozentsatzes wurden 103.982.020 ausstehende Aktien von VolitionRX zugrunde gelegt. Das Schedule 13G/A stellt ferner klar, dass die Beteiligung im gew枚hnlichen Gesch盲ftsverlauf gehalten wird und nicht zum Zweck der Einflussnahme auf die Kontrolle des Emittenten erworben wurde.
- Material disclosed stake: Reporting Person beneficially owns 11,705,000 shares (11.3%) of VolitionRX common stock.
- Clear authority: Reporting Person reports sole voting and sole dispositive power over all reported shares.
- None.
Insights
TL;DR: An investment manager holds an 11.3% passive stake with sole voting and dispositive power over the shares.
The Schedule 13G/A shows Lagoda Investment Management, L.P. exercises sole voting and dispositive authority over 11,705,000 shares of VolitionRX (11.3% of the 103,982,020 shares reported outstanding). Filing under Schedule 13G indicates the position is asserted to be passive and held in the ordinary course of business rather than for control purposes. For investors, a disclosed >5% ownership by an investment adviser is material disclosure of shareholder concentration but does not, per the filing, signal an active control campaign.
TL;DR: The holder reports sole voting rights on an 11.3% block while certifying passive intent under Schedule 13G.
The report identifies Fatima Dickey as the sole member of the General Partner with voting and dispositive powers through the adviser structure. The filing includes a certification that the securities were not acquired to change or influence control. This disclosure clarifies beneficial ownership and decision-making authority, which is relevant to board-level stewardship and investor engagement even if the filer claims passive status.
Lagoda Investment Management, L.P. comunica che i suoi conti gestiti detenevano 11.705.000 azioni ordinarie di VolitionRX Ltd al 30 giugno 2025, corrispondenti al 11,3% del capitale sociale in circolazione. La documentazione precisa che la Reporting Person dispone del potere di voto esclusivo e del potere dispositivio esclusivo su tutte le 11.705.000 azioni. Per il calcolo della percentuale il rapporto prende come riferimento un totale di 103.982.020 azioni in circolazione di VolitionRX. Lo Schedule 13G/A indica inoltre che la partecipazione 猫 detenuta nell'ordinario corso dell'attivit脿 e non 猫 stata acquisita con l'intento di influenzare il controllo dell'emittente.
Lagoda Investment Management, L.P. informa que sus cuentas gestionadas pose铆an 11.705.000 acciones ordinarias de VolitionRX Ltd al 30 de junio de 2025, lo que representa el 11,3% del total en circulaci贸n. La presentaci贸n indica que la Persona Informante tiene el voto exclusivo y el poder dispositvo exclusivo sobre las 11.705.000 acciones. Para calcular el porcentaje se usaron 103.982.020 acciones en circulaci贸n de VolitionRX. El Schedule 13G/A se帽ala que la participaci贸n se mantiene en el curso ordinario del negocio y no se adquiri贸 para influir en el control del emisor.
Lagoda Investment Management, L.P.電� 2025雲� 6鞗� 30鞚� 旮办 甏�毽� 瓿勳霌れ澊 VolitionRX Ltd鞚� 氤错喌欤� 11,705,000欤茧ゼ 氤挫湢頃橁碃 鞛堨溂氅� 鞚措姅 氚滍枆欤检嫕鞚� 11.3%鞐� 頃措嫻頃滊嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊電� 氤搓碃鞚�(Reporting Person)鞚� 鞚� 11,705,000欤� 鞝勲秬鞐� 雽�頃� 雼弲 鞚橁舶甓�瓿� 雼弲 觳橂秳甓�鞚� 氤挫湢頃橁碃 鞛堧嫟瓿� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 牍勳湪 靷办爼鞐愲姅 VolitionRX鞚� 齑� 氚滍枆欤检嫕靾� 103,982,020欤缄皜 靷毄霅橃棃鞀惦媹雼�. Schedule 13G/A鞐愲姅 鞚� 歆�攵勳澊 韱奠儊鞝侅澑 鞓侅梾頇滊彊鞚� 鞚柬櫂鞙茧 氤挫湢霅� 瓴冹澊氅� 氚滍枆鞚胳潣 歆�氚瓣秾鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲嫎鞚� 氚濏瀳瓿� 鞛堨姷雼堧嫟.
Lagoda Investment Management, L.P. rapporte que ses comptes g茅r茅s d茅tenaient 11 705 000 actions ordinaires de VolitionRX Ltd au 30 juin 2025, soit 11,3% des actions en circulation. le dossier pr茅cise que la personne d茅clarante d茅tient le pouvoir de vote exclusif et le pouvoir de disposition exclusif sur l鈥檈nsemble des 11 705 000 actions. Le pourcentage a 茅t茅 calcul茅 sur la base de 103 982 020 actions en circulation de VolitionRX. Le Schedule 13G/A indique par ailleurs que cette participation est d茅tenue dans le cadre normal des activit茅s et n鈥檃 pas 茅t茅 acquise dans le but d鈥檌nfluencer le contr么le de l鈥櫭﹎etteur.
Lagoda Investment Management, L.P. meldet, dass seine verwalteten Konten zum 30. Juni 2025 11.705.000 Stammaktien von VolitionRX Ltd hielten, was 11,3% der ausstehenden Aktien entspricht. Die Einreichung gibt an, dass die meldepflichtige Person 眉ber alle 11.705.000 Aktien alleiniges Stimmrecht und alleinige Verf眉gungsmacht besitzt. Zur Berechnung des Prozentsatzes wurden 103.982.020 ausstehende Aktien von VolitionRX zugrunde gelegt. Das Schedule 13G/A stellt ferner klar, dass die Beteiligung im gew枚hnlichen Gesch盲ftsverlauf gehalten wird und nicht zum Zweck der Einflussnahme auf die Kontrolle des Emittenten erworben wurde.
FAQ
How many VolitionRX (VNRX) shares does Lagoda Investment Management own?
What percentage of VNRX is owned by the reporting person?
Does Lagoda have voting control over the shares reported in the Schedule 13G/A?
Was the position filed as an attempt to influence control of VolitionRX?
Who signs the Schedule 13G/A for Lagoda Investment Management?
